Acelyrin Reaffirms Merger Deal With Alumis

MT Newswires Live03-04

Acelyrin (SLRN) and Alumis (ALMS) reaffirmed Tuesday their commitment to merge in an all-stock transaction, as Acelyrin said its board had determined that Concentra Biosciences' unsolicited indication of interest is "not reasonably expected to result in a superior proposal."

Acelyrin and Alumis said their combined company would have a pro forma cash position of about $737 million, which is expected to fund operating expenses and capital expenditure requirements into 2027.

Separately, Acelyrin said its board is confident that the Alumis deal would maximize long-term value for its stockholders.

The companies said they continue to expect their merger to close in Q2, subject to approval by the stockholders of both companies and other customary closing conditions.

Acelyrin shares were down more than 8% in recent trading while Alumis shares were up 0.4%.

Price: 2.46, Change: -0.23, Percent Change: -8.55

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment